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Abstract: There is in France and more generally in Europe a paradox. In the agro 
industry  business,  the  use  of  biotechnology  is  suspicious  and  controversy  (see  for 
example the emblematic case of GMOs), the subject is little debate in the health sector. 
Yet, in those two sectors, the production process of biotechnology is the same. How can 
we explain those differences?  
This article  aims to explain the  reasons for  the acceptance of  biotechnology in the 
business  of  health.  Health  professionals  interviewed  in  this  study  leave  use  the 
biotechnology as a tool to improve their practices and benefiting their patients. In doing 
so, they play a key role to facilitate their consumption by the public. 
This article is based on a qualitative and exploratory methodology. Our sample consists 
of leaders of biotech companies or selling biotechnology and doctors who use them. 
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INTRODUCTION 
The adaptation of diseases to the drug promotes the emergence of new forms of pathogens 
increasingly resistant. This phenomenon is causing the rise of new form of infections and loss of 
effectiveness of antibiotics and antiviral.  
The  globalization  of  trade  increases  the  speed  and  extent  of  spread  of  diseases  and 
promoting the transformation of these epidemics pandemics that affect a population so much 
larger as the example of the "Spanish flu" which made 21 million deaths between 1918 and 1920 
(Buisson et al., 2007). 
The pharmaceutical industry must develop new active ingredients faster and in greater 
volume.  The  adoption  of  biotechnology  has  brought  production  processes  suitable  for  mass 
consumption and promoted the development of a new strategy for research and development. 
However, while biotechnologies are in the food sector suspicion and controversy (such as the 
emblematic case of GMOs), the subject is little debate in the health sector. Yet the production 
process of biotechnology is the same. 
Thus, "Biotechnology is permitted restrictions are in medicine, which cures the disease, 
then they are dismissed without nuances in agriculture, which might cause. It is a cultural bias 
quite revealing. The European agrees to include in his body on medical prescription which he 
refuses to find the plate. Which enters into its veins by injection would be less dangerous than 
what  passes  through  his  stomach.  "(Neirynck,  2005).  Medical  applications  were  assimilated 
rapidly, agricultural applications have been subject to investigations, consultations and public 
                                                
1 Professor of management, Ph.D. 
2 Associate Professor, Ph.D. Bertrand PAUGET1, Xavier PARISOT1 
 
  86 
debates  and  the  moratorium  still  prevents  their  use  (Neirynck,  ibid.).  Even  when  medical 
biotechnology has been under discussion before use (Claeys et Huriet, 2000), as in the case of 
research on embryonic stem cells, this has rarely been followed by a ban (Milon, 2006).  
In the debate on agricultural biotechnology, the weight of inputs and the dangers are not 
treated equally. Potential risks monopolize all the attention and obliterates the potential profits. 
While in the case of so-called red biotechnology (or health), the therapeutic benefits weigh very 
heavy in the decision to use. This is reflected in the absence of studies specifically examining the 
acceptance  of  red  biotechnology.  This  article  therefore  proposes  to  establish  a  first  grid 
explaining this phenomenon. 
We seek to explore why the use of red biotechnology is no debate. We thus postulate that 
the approach is determined by their professional identity (Dubar, 2002): identity of a sectoral, 
identity associated with the manufacture of biotechnology on the other. 
We  focused  on  the  relation  between  the  producers  of  biotechnology  with  health 
professionals (ie the relationships Business to Business) as a part of an exploratory qualitative 
study based on ten interviews.  
We conclude that over the identity of actors is being questioned over the controversy on 
the dangers of biotechnology, including bio drugs, appears. It is in this sense a contamination of 
the debate on GMOs in the health sector. The assimilation of the innovation process could be 
affected at a time when it appears crucial to face the global warming & health epidemic are 
increasing. 
I. LITTERACY OVERVIEW 
Red  biotechnology  applications  are  very  diverse.  However,  they  have  in  common  the 
requirement to meet the standards of quality and safety defined by the public health code. These 
parameters are controlled by the AFSSAPS in the authorization process of placing on the market 
in France. Medicines derived from biotechnology and biopharmaceuticals are currently the main 
market segment of red biotechnology in terms of turnover. From producer to consumer, the 
actors involved are the laboratories, drug companies, the distributors and wholesalers, hospital 
and  other  distributors,  health  professionals  (mainly  doctors  who  prescribe  the  drugs)  and 
patients. 
Strong relationships are essential especially in the innovation process. Thus, researchers 
working with the hospital to test the efficacy of new active ingredients, patients' associations 
support research, industry working with surgeons to improve their tools, their materials, their 
techniques, the finance large private laboratories of R & D programs in the public sector ... 
Advances in medical biotechnology is therefore characterized by a strong interdependence of the 
actors. Their relationship is essential to allow or not the assimilation of biotechnology in society. 
The concept of relationship seems to be of some evidence: Clarkson (1995) quote “It is the 
first condition of being human. It is so obvious that it is frequently taken for granted, and so 
mysterious that many . . . have made it a focal point of a lifetime’s preoccupying passion”. 
However,  it  is  often  the  process  around  the  relationship  that  are  used  rather  than  the 
relationship itself or the actors who mobilize as outlined in earlier work (Pauget, 2006, Grenier 
and  Pauget,  2006).  Thus,  the  scope  of  the  strategy  involves  the  concepts  of  coordination, 
cooperation,  the  ethos  of  the  anthropology,  sociology  those  with  experience,  and  the  social 
norms... 
More recently, the concept of social network (Degen and Forse, 1994) has highlighted the ability 
of actors to use these relations. The social network has an intensity (Ahuja, 2000, Lemieux 
1999),  a  direction  (Coleman,  1989).  However,  very  little  is  said  about  the  content  of  the 
relationship.  The French Paradox: How can we explain the assimilation of Health Biotechnogies? 
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We postulate that this relationship is the foundation on which you can build acceptance of 
red biotechnology. We using the concept of professional identity (Dubar, 2002). The choice of 
this concept can be controversial. It was indeed possible to use previous work on recognition of 
physicians to their environment (Strauss, 1992) to analyze the relationship of physicians with 
other actors. 
In doing so, we would have relegated the producers of biotechnology to a subordinate 
place, which we believe is not their own. We have therefore preferred to make the opposite 
choice  on  more  particular  producers  of  biotechnology  in  their  relations  with  doctors.  
Identity  is  perceived  at  the  individual  and  collective  effort  as  a  general  representation  and 
positioning of actors in relation to individual goals, group or organization. The identity "is linked 
to  the  membership  of  certain  social  groups  and  the  emotional  and  evaluative  significance 
resulting  from  this  membership”  (Tajfel,  1992).  We  postulate  that  the  identity,  and  more 
particularly the one related to his profession, is the content structure of the relationship. It gives a 
sense and a direction to the relationship. 
Indeed, as we have previously stated in our previous work (Pauget, 2008), an actor creates 
and maintains a relationship, not with a view to achieving a common but according to his desire 
to be recognized. To achieve this recognition, it remains in the group or separates. The sense of 
belonging created by the creation of identity is reflected in what Halbwachs is defining by the 
word "thinking with others" (1994). But it is not possible to reduce the phenomenon of identity 
to the sense of belonging. There is indeed an adaptation of the actor in the process of building the 
relationship through the mobilization of an identity for himself (how am I positioned in relation 
to others, Mead, 1934). In addition, any relationship involves a contact with each other and 
therefore an identity to others (what a picture of me the other me back).  
Dubar summarizes this approach in a grid that we mobilize in this article.  
The  main  characteristic  of  red  biotechnology  is  the  way  were  built  manufacturing 
processes using biotechnologies. They are highly relational. However, two essential peculiarities 
influencing professional identity of the actors producing or using biotechnology can be used in 
relation to the literature:  
-  The first is the technical nature of biotechnology. “They are [...] based on cutting-edge 
scientific advances in biochemistry, cell biology, microbiology, process engineering and 
are characteristic of a high-tech industry”. (Hache, 2005). Their development has helped 
to meet the needs of industrial innovation in adapting to the sectors in which they were 
mobilized. This technicality is associated with a moral. Initially, biotechnology was seen 
as a possible way to increase the happiness of mankind. They were seen as able to help 
solve  the  problems  of  population,  food,  health  and  environment  (Bud,1993;  Debru, 
2003). This vision still corresponded to that of the philosophers of the Enlightenment: 
scientific progress should contribute to the progress and happiness of a civilization. If of 
course, these certainties have been largely depleted, they nevertheless continue to be used 
as arguments in favour of biotechnology.  
-  The second characteristic is that they are at work in the private capitalist sector. They are 
therefore  determined  by  the  rules  that  govern  this  type  of  economy:  search  for 
profitability,  development  applied  to  the  marketing  of  new  innovative  products, 
speculation. 
II. METHODOLOGY  
Our field of study lies in the health sector that uses biotechnology. We use the case method 
(Yin, 1991) in that it allows to integrate the economic and social weight and to better understand 
the specific organizations that have participated in our study. Our approach is based on a modest 
inductive approach, we used primary and secondary data.  Bertrand PAUGET1, Xavier PARISOT1 
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The primary data consist of semi-structured interviews (see annex). They were recorded and 
transcribed  so  as  to  understand  why  biotechnology  is  being  used  without  much  friction  or 
polemics. To this end, we had a total of ten interviews from ten different organizations. These 
are:  
- Five companies that are national manufacturer of bio products. We interviewed each of the CEI 
directly  concerned  with  the  problem  of  assimilation  of  biotechnology  on  the  market.  Their 
companies produce bio products to the health sector 
-Five  doctors  in  charge  of  hospital  or  clinical  services  that  all  use  bio  (mainly  drugs  and 
prostheses). They are all located in the north-eastern France. The choice fell on those responsible 
for  services  because  we  believe  they  were  best  able  to  take  a comprehensive  view  of  their 
responsibility  to  share  the  use  of  biotechnology  in  medical  practice.  Several  specialties  are 
represented, including cardiology, surgery (especially gastrointestinal), obstetrics.  
The questionnaire was is the same because we have built a sufficiently general to allow the 
expression  of  views  which  enlighten  us  in  different  ways  but  methodologically  comparable 
vision of biotechnology in the health sector. We want to understand, certainly ever exploratory 
how actors produce and use biotechnology for their assimilation. 
Our  study  focuses  on  the  producers  (the  biotech  companies  on  the  one  hand)  and 
physicians who are intermediate users of biotechnology. We analyze as well the "Business to 
Business” (B to B) the first part of the value chain of the drug. We postulate that in this phase 
that we can better analyze why the use is not a problem to producers and to health professionals. 
We analyzed the data and coded interviews according to the approach advocated by Miles and 
Huberman (1991).  
Our coding is formed by a matrix to determine the nature of professional identity for oneself or 
others against the two other variables influencing the biotechnology sector. 
Our secondary data consist of various materials. They both study reports parliamentary studies 
Inserm as brochures or pharmaceutical analysis ... This data can be divided: those dealing with 
the production of biotechnology in the health sector of a share and use their assimilation by the 
general public. They complement our primary data.  
This approach is part of a larger research project including end users, (patients) to gather 
their perceptions on these innovative products. Data were collected among the general public 
(ten) to the point against our assumptions and analysis but they were not included in this article. 
This research project considers biotechnology as an autonomous business ecosystem and whose 
codes and relational models deviate sometimes practices commonly accepted by society. Our 
posture intervention research (David, 2000) aims to reduce the gap to allow the expression of an 
informed debate in society and not dogmatic about the use of biotechnology. 
III. RESULTS AND DISCUSSION 
We note that there is in the light of our results two fields that can explain the assimilation 
of red biotechnology in society: the first is related to the changing structure of the health sector, 
the second based on the perception that producers and doctors of nature bioproduct they are from 
their point of view, a new range of tools among others.  
The structuring of the health sector made strong interdependencies was built around the 
figure of the doctor. In our interviews, they develop a discourse that is taken by producers of 
biotechnology, which revolves around the regulatory field of health. From this fact, the majority 
of respondents, it is not possible to do "anything" (Excerpt from interview). The use of bio is not 
regarded more or less dangerous than other products. 
On the ethical level, the importance of perceived risk is assessed according to specialty 
physicians and the sphere of application of bio-considered. Thus, cardiac and digestive surgery, The French Paradox: How can we explain the assimilation of Health Biotechnogies? 
 
  89 
doctors appear less affected by ethical issues in obstetrics. Regarding drugs, the origin of the 
active ingredient is described as negligible in terms of the effectiveness of treatment. Thus, in 
practice, very few perceived differences appear between  the  use of bio products and use  of 
products. What is important primarily for the doctor, the quality of the relationship with the 
patient and comfort meet the technology used. One doctor summed up this thinking: "I would 
say that I work in a specialty in which the biotechnology ... including the use of biotechnology 
does not lead to a debate too ... uh ... an ethical debate. In the sense that the ... in treating cardiac 
arrhythmias, one of the arteries leads uh ... there is not too much trouble. After if you start in 
obstetrics or medical specialties other than.. uh .. we can have an ethical debate that is much 
more  important  and  more  difficult.  The  only  ethical  debate  that  you  can  have  the  use  of 
biomaterials in cardiology is to know at what age it should stop, how far to go. But this is not the 
product  itself  that  is  at  issue  is  the  use  in  some  people.  ...So  there  are  some  products  of 
biotechnology which begs the question of the use in general "(Excerpt from interview, Doctor 1). 
Unlike  the  agricultural  biotechnology  sector,  where  lack  of  trust  among  stakeholders 
leading to the  expression of  extreme  positions, postures recorded among  participants in this 
study are rather homogeneous whether producers or doctors. Doctors say they are confident in a 
relatively protective medical sector without ignoring the potential risks are an inappropriate use 
of bioproducts, "Yes, everything that is effective, the same adage in medicine, all that is as for 
drugs, all that is very efficient and also potentially very dangerous. The more you are efficient, 
we can act and it is potentially more dangerous. "(Excerpt from interview, Doctor 2).  
This insurance prescribing is justified by the strong dependence of designers bio product doctors 
and  hospitals.  Indeed,  an  interaction  of  these  actors  is  essential  to  development  and  the 
development  of  new  therapies.  Combined  with  strong  regulatory  constraints,  these  reassure 
doctors about the quality and safety of treatments they prescribe: "The information is much more 
... they can not give information in the same way ... it's pretty regulated. But to meet and possibly 
on hand to explain things, it can be easily "(Excerpt from interview, Doctor 3). 
In logic of business to business ", the physicians who prescribes, play a central role as they 
determine which products should be used under what circumstances. They are the ones who 
shape the discourse that there are almost equivalent with the producers of biotechnology. 
However,  the  purpose  of  these  manufacturers,  mainly  for  specialists,  is  technical.  It 
combines the advantages of bio with the needs of prescribing physicians. Of all respondents, 
distributed  bio  products  are  indicated  for  the  treatment  of  diseases  with  high  unmet  need 
previously  (vaccines,  cancer,  infectious  diseases,  autoimmune  diseases,  and  bio-compatible 
implantable). When intellectual property rights exist, they make the captive market of users. It is 
therefore, the only therapeutic option available, the best alternative technique developed. The 
discourse of producers who have understood that this generates a strong attractiveness for bio, 
focuses on the contributions of their innovations. In their relationships with prescribers, these 
benefits are the cornerstone of the marketing strategy used by pharmaceutical. This action is 
sometimes reinforced by the organization of visits to plants greatly appreciated by physicians. 
Based  on  our  study,  it  is  difficult  to  determine  the  scope  and  intensity  of  interaction 
between producers and doctors on the postures adopted. Despite a higher level of extension, 
doctors  have  a  perception  of  biotechnology  similar  to  the  growers.  This  result  reflects  the 
complete  assimilation  of  medical  biotechnology  available  in  professional  practices.  
In addition, doctors and producers develop biotechnology as a toolbox that improves health. The 
use of this instrument is characterized by the mobilization of three types of arguments: 
1)  Biotechnology is old and therefore inherently low emissions. The decline can predict the 
side effects listed or against their use: "The first manipulation biotechnology ... we are 
acquired when it was ... when we studied the embryogenesis and when we examined the 
histology  [...]  because  already  at  that  time  then,  but  I  speak  of  60  years,  they  are Bertrand PAUGET1, Xavier PARISOT1 
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"manipulation"  that  did.  So  I  feel  what  is  called  biotechnology  currently  is  a  small 
industrial side, it may be a little pejorative, but it is my feeling. But as a purist, I would 
say  we  have  done  already  biotechnological  manipulations,  although  there  are  50 
"(Excerpt from interview, Doctor 3).  
2)  The biotechnology companies are involved in scientific and technical development. In 
this sense, it perpetuates the scientist view of science promoted by the Enlightenment 
over biotechnology scientists are, the more they can find new therapeutic approaches, 
more progress resulting benefit to patients. Doctors echo of this vision: "Uh, I mean by 
this that there was a shift from a technique that lasted 17 or 18 centuries and a century it 
has become a science and medicine in half a century scientific medicine hyper, hyper-
specialized, avant-garde ... "(Excerpt from interview, Doctor 3). 
3)  The  third  argument is more  specifically used by the producers  because it is oriented 
towards the needs of clients according to a capital "to health which seems logical, we 
have a number of drugs that may be produced either by bacteria or plants [...] if we have 
new technologies to modify plants, bah, so you can acquire new characteristics that may 
be useful in terms of production, in terms of approach, in terms conservation [...] So it 
was useful in relation to it "(Excerpt from interview, Producer 1). 
DISCUSSION 
Whether  from  the  perspective  of  both  producers  and  doctors,  we  were  struck  by  the 
convergence of speech as if a speech could not emerge from the producers of red biotechnology. 
Framed largely in a regulated medical field and regulated biotechnology are to them one more 
tool  in  a  therapeutic  practice  for  patients.  Considering  the  use,  doctors  and  producers  think 
exactly the same thing. 
For doctors, biotechnology is a toolkit that assists and improves their medical practice. 
Biotechnology does not transform their professional identity inherited from their work: it is an 
identity for itself that is mobilized.  
In contrast, producers mobilize others for an identity oriented towards the organization of 
production.  They  can  mobilize  only  very  fragmentary  speech  centred  on  mastery  of  the 
biotechnology sector, like biotechnology did not own a field, but just one field of application for 
doctors.  
In total, the trust relationship that has developed between the practitioners of biotechnology and 
health professionals focused on the doctor, because it is a legitimate figure. In the health sector, 
institutions  have  recovered  and  institutionalized  this  link  and  thus  the  assimilation  of 
biotechnology. 
 
The new trends:  
We note however, both in terms of our secondary sources as primary changes in several 
ways.  First,  the  status  of  the  physician  is  weakened  (Kervasdoué,  2003).  His  word  is  less 
legitimate. Thus, the nature of drugs prescribed may be questionable. However, the figure of the 
physician is central to the assimilation of biotechnology.  
Secondly, we see a desire among some of producers of biotechnology would "educate" 
their end users without necessarily going through the intermediary figure yet legitimate doctor. 
Thus networks laboratories patients are emerging to explain the properties of drugs directly to 
patients. So is this the case of certain diseases. This aims in a context of welfare state financial 
crisis,  and  generic  products.  However,  this  discourse  underpinned  by  logic  of  capital  (a 
marketing vision of health care) creates new relationships and representations, parallel to those 
we have presented. It seems necessary to explore this avenue of research, not contained in our The French Paradox: How can we explain the assimilation of Health Biotechnogies? 
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exploratory sample to find out how these relationships affect the uptake of biotechnology by 
patients. They act in addition to or in opposition of the doctor-patient relationship? Do they or do 
they hinder the assimilation of biotechnology?  
Finally, we noted the emergence in our sample of suspicion towards biotechnology. The 
doctor 4 said this:  
"For there any sectors where biotechnology advance that it helps in certain disease and there are 
other areas where we see it in biotechnology .., can be seen particularly in the sperm in men, is 
currently fashionable, it became increasingly compared to what the man had a few years ago so 
we can consider that biotechnology and modern developments currently reducing the number of 
sperm in humans, we are going to disappear "(extract from interview).  
There is a contamination of the debate on agricultural biotechnology to medical biotechnology. 
CONCLUSION  
In France, our relation to biotechnology is not the same after that we talk about agricultural 
biotechnology  or  those  related  to  health.  However,  there  is  a  paradox  that  medical 
biotechnologies  are  the  only  ones  allowed.  We  tried  to  explain  this  apparent  contradiction 
through this exploratory study.  
These are the bodies (physicians) and institutions (hospitals) that allow the medical use of 
biotechnology.  Lived  as  a  therapeutic  aid,  they  are  well  accepted.  But  this  vision  of 
biotechnology  is  related  to  trust  in  the  figure  of  the  doctor.  However,  it  is  questioned.  
We see through the results of our questionnaires, and more broadly through the media debate in 
France, the debate swirling contaminates agricultural biotechnology field of health. There is a 
suspicion that emerges vis-à-vis health-related biotechnologies.  
However, according to a swing of the pendulum, there is a risk that the stigma affects all 
red biotechnology. And instead to look at their use on a case by case - and judging from their 
potential  harmfulness  all-biotechnology  or  rejected.  What  could  happen  if  like  the  green 
biotechnology (e.g. GMO), the public refused to eat? What if such a drug was dangerous because 
it stigmatized was designed and produced from biotechnology? 
The model of therapeutic innovation of the pharmaceutical industry increasingly relies on 
the  use  of  biotechnology.  The  market  for  medicines  derived  from  molecular  biology  is 
experiencing a growth rate in value twice that of the overall market. In 2006, biopharmaceuticals 
account for 25% of global drug pipeline (Abecassis and Coutinet, 2008). Two times faster than 
that  recorded  in  the  medicines  (Leem,  2005),  the  proliferation  of  "blockbusters"  in 
biopharmaceuticals is often cited by those interviewed. If societal reasons will challenged the 
employment of biopharmaceuticals in its entirety, would we be able to imagine alternatives, 
while the number and recurrence of epidemics or pandemics, accelerating? It is likely that not.  
It would therefore seem appropriate to obtain an informed debate and to create a new 
representation of biotechnology red, less related to legitimate and figures based on knowledge 
co-constructed by stakeholders. It should nevertheless bear in mind, as pointed out by a doctor 
that any  drug is dangerous or not  built from biotechnology, and that any risk can never be 
excluded. Or do we prefer the biotech scapegoat cathartic rejection of science that has failed in 
his attempt to become a reality the vision of the progress promised by the philosophical vision of 
science born in the XVIII
th century? 
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Annexe 1 
A propos de vous 
Q1 Quelle est votre profession ?   
Q2 Quel est votre âge ?   
Q3 Quelle est la date de votre entrée dans les biotechnologies ?   
Q4  Quelle est la date de votre entrée dans votre société ?   
Q5 Depuis quand travaille-t-elle dans les biotechnologies ?   
￿ ￿ ￿ ￿  ￿ ￿ ￿ ￿  ￿ ￿ ￿ ￿  ￿ ￿ ￿ ￿ 
Q6a Comment avez-vous connu les biotechnologies ?  Par un 
professionnel 
Par   Par  Autre :  
 
Q6b Quelles sont vos fonctions au sein de votre entreprise ? 
 
Membre d’un autre conseil d’administration  ￿ ￿ ￿ ￿ 
Elu des chambres de commerces et d’industrie  ￿ ￿ ￿ ￿ 
Membre d’une association  ￿ ￿ ￿ ￿ 
Représentant du personnel  ￿ ￿ ￿ ￿ 
Q6c Exercez vous d’autres fonctions ? 
Autre(s), Précisez :  ￿ ￿ ￿ ￿ 
Q7 – Exercez vous une autre fonction dans les 
biotechnologies ? 
Oui ￿  Non ￿ 
Q7 a : Si oui préciser :  
 
Q7b – Avez-vous quitté l’une de ces fonctions ?  
 
Oui ￿  Non ￿ 
8-1 Par contraintes de temps   ￿ ￿ ￿ ￿ 
8-2 Par éthique personnelle  ￿ ￿ ￿ ￿ 
8-3 Par désaccord personnel  ￿ ￿ ￿ ￿ 
Q8a  -Si oui, pour quelles raisons ?  
(plusieurs réponses possibles) 
8-4 Autre(s), Précisez :  ￿ ￿ ￿ ￿ 
 
A propos des biotechnologies 
Comment d’une manière générale jugez vous les biotechnologies ? 
￿  ￿  ￿  ￿  Q9 – Pensez vous que les biotechnologies soient bénéfiques 
pour l’Homme ?   Non  Plutôt non  Plutôt oui  Oui 
 
Q10 Comment définiriez vous les biotechnologies ? 
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Q11 – Utilise-t-on les biotechnologies dans le secteur de ?  
￿  ￿  ￿  ￿  A – L’énergie 
NON  Plutôt non  Plutôt oui  OUI 
￿  ￿  ￿  ￿  B – Le transport  
NON  Plutôt non  Plutôt oui  OUI 
￿  ￿  ￿  ￿  C – La santé  
NON  Plutôt non  Plutôt oui  OUI 
￿  ￿  ￿  ￿  D -  l’agro alimentaire 
NON  Plutôt non  Plutôt oui  OUI 
Q12 Pourquoi utilise-t-on les biotechnologies dans ces secteurs d’activités ? 
 
 
 
 
 
 
 
 
 
Le questionnaire total représente six pages et cinquante et une question. Certaines questions 
contiennent des sous thème ou de multiples réponses comme dans le cas de la question 11. 
L’ensemble s’articule autour des trois variables retenues dans notre article (Cf. partie I).  